ABSTRACT
BACKGROUND: There is increasing evidence of the key role that the gut microbiota plays in inflammatory diseases. OBJECTIVES: To identify differences in the faecal microbial composition of patients with psoriasis compared with healthy individuals in order to unravel the microbiota profiling in this autoimmune disease. METHODS: 16S rRNA gene sequencing and bioinformatic analyses were performed with the total DNA extracted from the faecal microbiota of 19 patients with psoriasis and 20 healthy individuals from the same geographic location. RESULTS: Gut microbiota composition of patients with psoriasis displayed a lower diversity and different relative abundance of certain bacterial taxa compared with healthy individuals. CONCLUSIONS: The gut microbiota profile of patients with psoriasis displayed a clear dysbiosis that can be targeted for microbiome-based therapeutic approaches. What's already known about this topic? Psoriasis is a chronic inflammatory immune-mediated skin disease, the aetiology of which remains unclear. The human microbiota is a complex microbial community that inhabits our body and has been related with the maintenance of a healthy status. Several studies have focused on the skin microbiome and its connection with psoriasis although less attention has been focused on the potential role of the gut microbiota in psoriatic disease. What does this study add? This study unravels the gut microbiome dysbiosis present in a cohort of patients with psoriasis, compared with a healthy control group from the same geographical location. This study shows a lower bacterial diversity and different relative abundance of certain bacterial taxa in patients with psoriasis. We gain knowledge and insight into the microbiome alterations in psoriatic disease, opening new avenues for therapeutic approaches to reshape the human microbiome towards a healthy status.
Subject(s)
Dysbiosis/complications , Gastrointestinal Microbiome/immunology , Psoriasis/immunology , Adult , Cohort Studies , DNA, Bacterial/isolation & purification , Dysbiosis/diagnosis , Dysbiosis/immunology , Dysbiosis/microbiology , Feces/microbiology , Female , Gastrointestinal Microbiome/genetics , Healthy Volunteers , Humans , Male , Middle Aged , Psoriasis/microbiology , RNA, Ribosomal, 16S/geneticsABSTRACT
No disponible
Subject(s)
Humans , Male , Aged , Lupus Erythematosus, Cutaneous/chemically induced , Lupus Erythematosus, Cutaneous/complications , Lupus Erythematosus, Cutaneous/diagnosis , Interferon-alpha/antagonists & inhibitors , Interferon-alpha , Lupus Erythematosus, Cutaneous/drug therapy , Lupus Erythematosus, Cutaneous/etiology , Lupus Erythematosus, Cutaneous/therapy , Interferon-alphaABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Hamartoma/diagnosis , Hamartoma/etiology , Hamartoma/therapy , Hamartoma/complications , Hamartoma/immunology , Hamartoma/pathologyABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Scleroderma, Localized/diagnosis , Lichen Sclerosus et Atrophicus/diagnosis , Influenza Vaccines/adverse effects , Methotrexate/therapeutic use , Ultraviolet TherapySubject(s)
Influenza Vaccines/adverse effects , Lichen Sclerosus et Atrophicus/etiology , Scleroderma, Localized/etiology , Aged , Breast Neoplasms , Female , Humans , Lichen Sclerosus et Atrophicus/drug therapy , Methotrexate/therapeutic use , PUVA Therapy , Prednisone/therapeutic use , Scleroderma, Localized/drug therapyABSTRACT
No disponible
